SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001299265-16-000008
Filing Date
2016-06-28
Accepted
2016-06-28 14:32:25
Documents
1
Group Members
MARK NORDLICHTPLATINUM LIQUID OPPORTUNITY MANAGEMENT (NY) LLCPLATINUM MANAGEMENT (NY) LLCPLATINUM PARTNERS LIQUID OPPORTUNITY MASTER FUND L.P

Document Format Files

Seq Description Document Type Size
1 d13v4.htm SC 13D/A 135118
  Complete submission text file 0001299265-16-000008.txt   136975
Mailing Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017
Business Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Subject) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-43603 | Film No.: 161735742
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 250 WEST 55TH STREET 14TH FLOOR NEW YORK NY 10019
Business Address 250 WEST 55TH STREET 14TH FLOOR NEW YORK NY 10019 212-582-2222
Platinum Partners Value Arbitrage Fund, LP (Filed by) CIK: 0001299265 (see all company filings)

IRS No.: 141861954 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D/A